Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYCP | ISIN: US34960Q2084 | Ticker-Symbol: CNB0
Frankfurt
06.06.25 | 15:29
7,500 Euro
+4,90 % +0,350
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FORTRESS BIOTECH INC PREF Chart 1 Jahr
5-Tage-Chart
FORTRESS BIOTECH INC PREF 5-Tage-Chart

Aktuelle News zur FORTRESS BIOTECH INC PREF Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoFortress Biotech, Inc. - 8-K, Current Report1
30.05.Fortress Biotech, Inc.: Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics159MIAMI, May 30, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value...
► Artikel lesen
15.05.Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights181Emrosi commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint...
► Artikel lesen
16.04.Fortress Biotech, Inc. - 8-K, Current Report2
FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln
31.03.Fortress Biotech, Inc. - 10-K, Annual Report3
31.03.Fortress Biotech, Inc.: Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights75Emrosi approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary...
► Artikel lesen
25.03.Fortress Biotech FY 2024 Earnings Preview2
17.03.Fortress Biotech kooperiert mit Partex für KI-gestützte Arzneimittelentwicklung7
17.03.Fortress Biotech, Inc.: Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform144FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress"), an innovative biopharmaceutical company, today announced a strategic...
► Artikel lesen
10.03.Fortress Biotech, Inc. - 8-K, Current Report2
27.01.Fortress Biotech, Inc.: Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT192Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the...
► Artikel lesen
16.01.Fortress Biotech, Inc. - 8-K, Current Report3
06.01.Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease181Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones...
► Artikel lesen
06.01.Fortress Biotech, Inc. - 8-K, Current Report-
16.12.24Fortress Biotech, Inc. - 8-K, Current Report8
14.11.24Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights242Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally...
► Artikel lesen
13.08.24Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights261PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab to...
► Artikel lesen
25.07.24Fortress Biotech, Inc.: Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027359MIAMI, July 25, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress", or the "Company"), an innovative biopharmaceutical company focused on acquiring and advancing assets to...
► Artikel lesen
14.06.24Dividendenbekanntmachungen (14.06.2024)17.461 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  AARONS COMPANY INC  US00258W1080  0,125 USD  0,1163 EUR  ADAMS RESOURCES & ENERGY INC  US0063513081  0,24 USD  0,2234 EUR  AEGON LTD  BMG0112X1056 - 0...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1